Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | SPYK04 |
| Synonyms | |
| Therapy Description |
SPYK04 is a MAP2K1/2 (MEK1/2) inhibitor, which potentially increases Raf-Mek binding to inhibit feedback activation of Mek1/2 and inhibit tumor growth (J Clin Oncol 2025 43: 16_suppl, 3100). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| SPYK04 | SPYK 04|SPYK-04 | MEK1 Inhibitor 28 MEK2 Inhibitor 26 | SPYK04 is a MAP2K1/2 (MEK1/2) inhibitor, which potentially increases Raf-Mek binding to inhibit feedback activation of Mek1/2 and inhibit tumor growth (J Clin Oncol 2025 43: 16_suppl, 3100). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04511845 | Phase I | SPYK04 | A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion). | Active, not recruiting | USA | 1 |